MEXICOS STEELMAKERS LINE UP TO ORDER HYL-III

被引：0
|
作者：
不详
机构：
来源：
E&MJ-ENGINEERING AND MINING JOURNAL | 1980年 / 181卷 / 12期
关键词：
D O I：
暂无
中图分类号：
TD [矿业工程];
学科分类号：
0819 ;
摘要：
引用
收藏
页码：78 / &
相关论文
共 48 条
  • [41] Specific heat anomalies on the vortex melting line in YBa2Cu3O7-delta up to B=23 teslas: Observation of first- and second-order transitions, effect of oxygen doping, field orientation, crystal purity and detwinning.
    Junod, A
    Roulin, M
    Genoud, JY
    Revaz, B
    Walker, E
    Erb, A
    Marcenat, C
    Calemczuk, R
    Bouquet, F
    PHYSICA C, 1997, 282 : 1425 - 1426
  • [42] 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
    Verschraegen, C.
    Andric, Z. G.
    Moiseenko, F. V.
    Makharadze, T.
    Oleksiienko, A.
    Ruiz, E. P. Yanez
    Kim, S. H.
    Ahn, K.
    Park, T. H.
    Ju, H. A.
    Baek, E. H.
    Kwon, S.
    Lee, S. J.
    Chang, I.
    Kim, S. H.
    Kim, H. A.
    Lee, E.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1648 - S1649
  • [43] 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
    Morschhauser, Franck
    Radford, John
    Van Hoof, Achiel
    Botto, Barbara
    Rohatiner, Ama Z. S.
    Salles, Gilles
    Soubeyran, Pierre
    Tilly, Herve
    Bischof-Delaloye, Angelika
    van Putten, Wim L. J.
    Kylstra, Jelle W.
    Hagenbeek, Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) : 1977 - +
  • [44] 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
    Verschraegen, C.
    Andric, Z. G.
    Ciuleanu, T-E.
    Moiseenko, F. V.
    Makharadze, T.
    Shevnia, S.
    Oleksiienko, A.
    Yanez Riuz, E.
    Kim, S. H.
    Ahn, K. Y.
    Park, T. H.
    Park, S.
    Baek, E. H.
    Kwon, S.
    Ju, H. A.
    Lee, S. J.
    Kim, S. H.
    Kim, H. A.
    Lee, E. K.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1024 - S1025
  • [45] REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria
    Galle, Peter Robert
    Kudo, Masatoshi
    Llovet, Josep M.
    Cheng, Ann-Lii
    Lencioni, Riccardo
    Oviedo, Yanina
    Desai, Kalpna
    Monier, Amandine
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC)
    Tsuburaya, A.
    Narahara, H.
    Imamura, H.
    Hatake, K.
    Imamoto, H.
    Esaki, T.
    Kato, M.
    Furukawa, H.
    Hamada, C.
    Sakata, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients
    Hagenbeek, Anton
    Radford, John
    Van Hoof, Achiel
    Vitolo, Umberto
    Rohatiner, Ama Z. S.
    Salles, Gilles
    Soubeyran, Pierre
    Tilly, Herve
    Delaloye, Angelika Bischof
    van Putten, Wim L. J.
    Morschhauser, Franck
    BLOOD, 2010, 116 (21) : 261 - 262
  • [48] Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) plus /- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
    Rugo, Hope S.
    Barry, William T.
    Moreno-Aspitia, Alvaro
    Lyss, Alan
    Huebner, Luke
    Mayer, Erica L.
    Naughton, Michael
    Layman, Rachel M.
    Carey, Lisa A.
    Somer, Robert A.
    Toppmeyer, Debra
    Velasco, Mario
    Perez, Edith A.
    Hudis, Cliff A.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
12345